John Denham has called on the Southampton City Primary Care Trust (PCT) to allow the prescription of a cancer care drug. The drug (Alimta) is used to help people suffering from mesothelioma which is a disease related to exposure to asbestos. The PCT is not allowing it to be prescribed while the National Institute for Clinical Excellence (NICE) considers an appeal against its decision to recommend the drug. The drug is available in some other parts of England where mesolthelioma is common.

John Denham said "The incidence of asbestos-related disease is high in Southampton as a legacy of the shipbuilding and other heavy industries. I have urged the PCT to reconsider their decision so that this drug, which can help to extend the lives of mesothelioma sufferers, can be prescribed in Southampton."

NICE had issued guidance approving the use of this drug but that has subsequently been challenged by an appeal and NICE has not yet issued its final guidance. Southampton PCT has decided not to make Alimta available pending the final NICE decision.

John Denham continued "While I accept that PCTs do not have to prescribe drugs that are subject to an appeal to NICE, I understand that the appeal is on narrow technical issues that are very unlikely to change the decision in favour of Alimta. Alimta does not cure mesothelioma, but it can provide precious months of extra life. It would be very harsh if some of my constituents found out too late that the drug will be available in Southampton. I hope they will reconsider this decision soon."